To explore whether targeting ARK5 could prevent further progression of established fibrosis in vivo, we used ARK5-specific inhibitor HTH-01-015 to treat CCl4-induced mouse fibrosis models (Figure 8A). This evidence concerns the gene NUAK1 and fibrosis.